Key facts
- OncoGenomX’s last known valuation is $16.0M (Dec 2024).
- It has raised $1.0M.
- Notable investors include Venture Kick, 28DIGITAL, Gold Track, Tech4Eva.
- Status: Privately Held (backing).
Investors
4- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for OncoGenomX
- ·The full record, as it builds
Funding rounds
No funding rounds for OncoGenomX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OncoGenomX
Developer of an artificial intelligence-decision learning prediction software support service designed to eliminate uncertainty in cancer treatment by providing precise drug-tumor matching solutions. The company's software is grounded in human data and trained to understand the genetic and biological ramifications of treatment efficacy and treatment resistance of individual breast cancers and the gene suite, enabling healthcare professionals to have permanent disease control and better life expectancy for patients.
- Sector
- Healthcare
- HQ
- Allschwil, Switzerland
- Founded
- 2019
- Employees
- 8
- Website
- oncogenomx.ch/
- Ownership
- Privately Held (backing)
OncoGenomX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OncoGenomX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OncoGenomX in its N-PORT filings yet. We sweep new filings monthly.